6-K
MindWalk Holdings Corp. (HYFT)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 6-K
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16
OF THE SECURITIES EXCHANGE ACT OF 1934
For the month of September, 2025.
Commission File Number: 001-39530
ImmunoPrecise Antibodies Ltd.
Industrious 823 Congress Ave Suite 300 Austin, Texas 78701
(Address of principal executive office)
Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.
| Form 20-F ☒ | Form 40-F ☐ |
|---|
EXHIBIT INDEX
| Exhibit | Description |
|---|---|
| 99.1 | Press Release dated September 2, 2025 |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| IMMUNOPRECISE ANTIBODIES LTD. | ||
|---|---|---|
| Date: September 2, 2025 | ||
| By: | /s/ Jennifer Bath | |
| Name: | Jennifer Bath | |
| Title: | President and Chief Executive Officer |
EX-99.1
ImmunoPrecise Antibodies to Participate at H.C. Wainwright's 27th Annual Global Investment Conference in New York
AUSTIN, Texas, September 2nd, 2025 – ImmunoPrecise Antibodies Ltd. (the “Company” or “IPA”) (NASDAQ: IPA), today announced that it will participate in the 27th Annual H.C. Wainwright Global Investment Conference, taking place September 8th through September 10th, 2025.
Dr. Jennifer Bath, President CEO of IPA, will deliver a company presentation and be available for one-on-one investor meetings throughout the event.
Event Details:
- Conference: 27th Annual H.C. Wainwright Global Investment Conference
- Date: September 8-10th, 2025
Investors interested in scheduling a meeting with the IPA management team should contact their H.C. Wainwright representative or email meetings@hcwco.com
About ImmunoPrecise Antibodies Ltd.
ImmunoPrecise Antibodies Ltd. (NASDAQ: IPA) is a biotherapeutics company focused on the discovery and development of next-generation biologics. The Company combines scientific expertise with proprietary technologies—such as its LENSai™ platform—to accelerate drug discovery and improve decision-making across complex biological systems. IPA supports global partners in advancing novel therapeutics, diagnostics, and translational research. For more information, visit www.ipatherapeutics.com.
Investor Contact Louie Toma, CPA, CFA
Managing Director, CoreIR investors@ipatherapeutics.com
Source: ImmunoPrecise Antibodies Ltd.